Перспективы использования современных методов лекарственной терапии миомы матки

Обложка

Цитировать

Полный текст

Аннотация

В представленном обзоре литературы рассматриваются варианты лечения миомы матки у женщин репродуктивного возраста, основанные на современных возможностях патогенетической терапии.

Об авторах

Ярослав Олегович Стыкин

Российский университет дружбы народов

Email: stikyar@inbox.ru

Татьяна Вадимировна Галина

Российский университет дружбы народов

Email: tatyana.galina1@mail.ru

Список литературы

  2. Carbonell J.L., Acosta R. et al. Treatment of Uterine Myoma with 2.5 or 5mg Mifepristone Daily during 3 Months with 9 Months. Posttreatment Followup: Randomized Clinical Trial. 2013. No. 2. P. 2-6.
  3. Chwalisz K., DeManno D., Garg R. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin. Reprod. Med. 2004. Vol. 22. Iss. 2. P. 113-119.
  4. Croxtall J.D. Ulipristal acetate: in uterine fibroids. Drugs. 2012. Vol. 72. Iss. 8. P. 1075-1085.
  5. Cobellis L., Pecori E., Cobellis G. Comparison of intramural myomectomy scar after laparotomy or laparoscopy. Int. J. Gynaecology Obstetrics. 2004. Vol. 84. Iss. 1. P. 87-93.
  6. Donnez J., Tatarchuk T.F., Bouchard P. et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012. Vol. 366. Iss. 5. P. 409-420.
  7. Donnez J., Tomaszewski J., Vazquez F. et al. For the PEARL III Study Group. Long term treatment. Gynecology and Menopause. 2014. P. 9-18.
  8. Donnez J., Tomaszewski J., Vázquez F. et al. Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. N. Engl. J. Med. 2012. Vol. 366. P. 421-432.
  9. Engman M., Granberg S. et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 2009. No. 8. P. 18-21.
  10. Hoellen F., Griesinger G., Bohlmann M.K. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother. 2013.
  11. Levens E.D., Potlog-Nahari C. et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol. 2008. Vol. 111. Iss. 5. P. 1129-1136.
  12. Lethaby A., Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). Clin. Evid. (Online). 2011.
  13. Maruo T., Ohara N. et al. Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas. Expert Opin. Drug Discov. 2011. Vol. 6. Iss. 9. P. 897-911.
  14. Melis G.B., Piras B. et al. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin. Drug Metab. Toxicol. 2012. Vol. 10. P. 34-38.
  15. Radzinsky V.E., Fuks A.M. Gynecology. Geotar-media, 2014. Р. 1000.
  16. Roeder H., Jayes F. et al. CDB-4124 does not cause apoptosis in cultured fibroid cells. Reprod. Sci. 2011. Vol. 18. Iss. 9. P. 850-857.
  17. Su Y., Lian Q.Q., Ge R.S. Contraceptives with novel benefits. Expert Opin. Investig. Drugs. 2012. Vol. 21. Iss. 1. P. 83-90.
  18. Shtoch E.A., Tschai V.B. Uterine leiomyoma. Modern understanding of the pathogenesis and risk factors. Siberian medical review. 2015. No. 1. Р. 45-48.
  19. Szamatowicz М., Kotarski J. Selective progesterone receptor modulator (ulipristal acetate-a new option in the pharmacological treatment of uterine fibroids in women. Ginekol. Pol. 2013. Vol. 84. Iss. 3. P. 219-222.
  20. Tristan M., Orozco L.J. et al. Mifepristone for uterine fibroids. Cochrane Database Syst. Rev. 2012. No. 2.
  21. Tichomirov A.L. New features of pathogenetic treatment of uterine fibroids. Gynecology. 2013. Vol. 6. Iss. 15. P. 36-38.
  22. Radzinsky V.E., Totchiev G.F. Uterine fibroids: a course on organ preservation. News bulletin. Media bureau Status Presens. 2014. P. 24.
  23. Yoshida S., Ohara N. et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010. Vol. 28. Iss. 3. P. 260-273.

© Стыкин Я.О., Галина Т.В., 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах